Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EXAS Exact Sciences	$45.67 -3.0%	$50.32	$40.62 ▼ $79.62	$8.48B	1.25	2.62 million shs	1.52 million shs
FOLD Amicus Therapeutics	$8.62 -0.8%	$9.34	$8.55 ▼ $12.65	$2.65B	0.69	2.41 million shs	3.05 million shs
HOLX Hologic	$60.80 -1.8%	$65.89	$60.33 ▼ $84.67	$13.64B	0.97	2.52 million shs	2.38 million shs
SNY Sanofi	$55.45 -0.9%	$54.70	$45.22 ▼ $60.12	$140.72B	0.58	2.27 million shs	3.95 million shs
TAK Takeda Pharmaceutical	$15.05 +0.3%	$14.00	$12.58 ▼ $15.31	$47.89B	0.46	1.80 million shs	1.70 million shs

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EXAS Exact Sciences	+3.22%	+4.23%	-4.41%	-18.96%	-24.17%
FOLD Amicus Therapeutics	-3.55%	-4.71%	-5.44%	-11.24%	-24.63%
HOLX Hologic	+0.68%	+0.11%	-4.00%	-14.85%	-17.77%
SNY Sanofi	-1.70%	-5.07%	+2.70%	+15.82%	+16.35%
TAK Takeda Pharmaceutical	-1.18%	-1.05%	+6.68%	+14.01%	+4.20%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EXAS Exact Sciences	4.3997 of 5 stars	4.5	1.0	0.0	4.7	3.0	1.7	0.6
FOLD Amicus Therapeutics	4.2103 of 5 stars	3.4	1.0	0.0	4.3	3.5	0.8	1.9
HOLX Hologic	4.9465 of 5 stars	4.2	5.0	0.0	4.3	2.8	1.7	2.5
SNY Sanofi	3.7771 of 5 stars	2.5	4.0	2.5	0.0	3.3	0.0	3.1
TAK Takeda Pharmaceutical	2.8207 of 5 stars	0.0	3.0	2.5	0.0	3.2	0.0	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EXAS Exact Sciences	2.90	Moderate Buy	$70.83	55.10% Upside
FOLD Amicus Therapeutics	2.78	Moderate Buy	$16.75	94.32% Upside
HOLX Hologic	2.41	Hold	$84.62	39.17% Upside
SNY Sanofi	3.00	Buy	$62.50	12.71% Upside
TAK Takeda Pharmaceutical	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest EXAS, HOLX, FOLD, TAK, and SNY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/21/2025	SNY Sanofi	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$65.00
3/13/2025	EXAS Exact Sciences	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Perform	$52.00
3/4/2025	HOLX Hologic	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$80.00 ➝ $70.00
3/3/2025	HOLX Hologic	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
2/26/2025	EXAS Exact Sciences	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$75.00 ➝ $70.00
2/24/2025	EXAS Exact Sciences	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$70.00 ➝ $73.00
2/20/2025	EXAS Exact Sciences	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
2/20/2025	EXAS Exact Sciences	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$70.00 ➝ $65.00
2/20/2025	EXAS Exact Sciences	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$72.00 ➝ $65.00
2/20/2025	FOLD Amicus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$18.00 ➝ $17.00
2/20/2025	FOLD Amicus Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold

(Data available from 3/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EXAS Exact Sciences	$2.76B	3.07	$5.20 per share	8.79	$12.93 per share	3.53
FOLD Amicus Therapeutics	$528.30M	5.01	N/A	N/A	$0.63 per share	13.68
HOLX Hologic	$4.04B	3.38	$5.20 per share	11.69	$21.27 per share	2.86
SNY Sanofi	$44.29B	3.18	$5.46 per share	10.16	$33.20 per share	1.67
TAK Takeda Pharmaceutical	$4.58T	0.01	$3.52 per share	4.27	$15.39 per share	0.98

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EXAS Exact Sciences	-$204.15M	-$5.57	N/A	91.34	N/A	-37.29%	-5.29%	-2.45%	5/6/2025 (Estimated)
FOLD Amicus Therapeutics	-$151.58M	-$0.18	N/A	20.05	1.51	-10.62%	12.44%	2.60%	5/8/2025 (Estimated)
HOLX Hologic	$789.50M	$3.17	19.18	13.16	2.14	18.42%	19.72%	10.94%	5/1/2025 (Estimated)
SNY Sanofi	$6.02B	$2.49	22.27	11.67	1.01	12.77%	25.61%	14.72%	4/24/2025 (Estimated)
TAK Takeda Pharmaceutical	$994.06M	$0.40	37.63	9.12	0.24	4.53%	9.39%	4.53%	5/8/2025 (Estimated)

Latest EXAS, HOLX, FOLD, TAK, and SNY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
2/19/2025	Q4 2024	EXAS Exact Sciences	-$0.29	-$0.06	+$0.23	-$4.67	$701.45 million	$713.42 million
2/5/2025	Q1 2025	HOLX Hologic	$1.02	$1.03	+$0.01	$0.87	$1.02 billion	N/A
1/30/2025	Q4 2024	SNY Sanofi	$0.70	$0.70	N/A	$0.29	$10.57 billion	N/A
1/30/2025	Q3 2025	TAK Takeda Pharmaceutical	$0.34	$0.42	+$0.08	$0.05	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EXAS Exact Sciences	N/A	N/A	N/A	N/A	N/A
FOLD Amicus Therapeutics	N/A	N/A	N/A	N/A	N/A
HOLX Hologic	N/A	N/A	N/A	N/A	N/A
SNY Sanofi	$1.47	2.65%	+1.84%	59.04%	N/A
TAK Takeda Pharmaceutical	$0.53	3.52%	-8.36%	132.50%	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EXAS Exact Sciences	0.97	2.15	1.93
FOLD Amicus Therapeutics	2.01	3.39	2.42
HOLX Hologic	0.52	3.49	2.78
SNY Sanofi	0.15	1.46	1.14
TAK Takeda Pharmaceutical	0.63	1.31	0.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EXAS Exact Sciences	88.82%
FOLD Amicus Therapeutics	N/A
HOLX Hologic	94.73%
SNY Sanofi	14.04%
TAK Takeda Pharmaceutical	9.17%

Insider Ownership

Company	Insider Ownership
EXAS Exact Sciences	1.36%
FOLD Amicus Therapeutics	2.20%
HOLX Hologic	1.88%
SNY Sanofi	1.00%
TAK Takeda Pharmaceutical	0.04%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EXAS Exact Sciences	6,400	185.76 million	182.56 million	Optionable
FOLD Amicus Therapeutics	480	307.24 million	292.23 million	Optionable
HOLX Hologic	6,940	224.39 million	220.17 million	Optionable
SNY Sanofi	91,600	2.54 billion	2.51 billion	Optionable
TAK Takeda Pharmaceutical	47,300	3.18 billion	3.18 billion	Optionable

EXAS, HOLX, FOLD, TAK, and SNY Headlines

Recent News About These Companies

Takeda Pharmaceutical (NYSE:TAK) Sets New 12-Month High - Time to Buy?

March 25 at 9:48 AM | marketbeat.com

Cell and gene therapy market set to grow at 44% CAGR through 2030, reveals GlobalData

March 25 at 1:34 AM | financialexpress.com

Global pharma giants double down on China, betting on long-term growth

March 24 at 3:31 PM | globaltimes.cn

Summit Global Investments Has $9.66 Million Stake in Takeda Pharmaceutical Company Limited (NYSE:TAK)

March 23 at 5:49 AM | marketbeat.com

69,083 Shares in Takeda Pharmaceutical Company Limited (NYSE:TAK) Bought by Boston Partners

March 23 at 4:24 AM | marketbeat.com

Natixis Advisors LLC Acquires 21,539 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

March 23 at 3:54 AM | marketbeat.com

BioLife invests $4M to recycle biohazardous plastic waste

March 21, 2025 | plasticsnews.com

Signaturefd LLC Raises Stake in Takeda Pharmaceutical Company Limited (NYSE:TAK)

March 21, 2025 | marketbeat.com

Is Takeda Pharmaceutical Co. (TAK) a Great Value Stock Right Now?

March 19, 2025 | zacks.com

Takeda Pharmaceutical (NYSE:TAK) Hits New 12-Month High - What's Next?

March 18, 2025 | marketbeat.com

Protagonist Therapeutics Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2025

March 18, 2025 | miamiherald.com

Takeda Pharmaceutical Company Limited (NYSE:TAK) Position Lowered by Brandes Investment Partners LP

March 16, 2025 | marketbeat.com

TAK or DSNKY: Which Is the Better Value Stock Right Now?

March 14, 2025 | zacks.com

Fierce Pharma Asia—Takeda's oncology focus; Sun's Checkpoint buy; Ono-Ionis antisense deal

March 14, 2025 | fiercepharma.com

Japan union group says gained hefty average 2025 pay hike, albeit less than last year

March 14, 2025 | msn.com

Major Japan union group says agreements struck for average 5.37% pay hike

March 13, 2025 | msn.com

Takeda: Buy Into Future Drug Pipeline Potential, Despite Recent Profit Headwinds

March 13, 2025 | seekingalpha.com

Callan Family Office LLC Buys Shares of 19,924 Takeda Pharmaceutical Company Limited (NYSE:TAK)

March 11, 2025 | marketbeat.com

Mass. man gets prison time for defrauding Takeda Pharmaceutical Co. of $2.3M

March 11, 2025 | msn.com

Naviter Wealth LLC Has $228,000 Stock Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

March 10, 2025 | marketbeat.com

US Bancorp DE Has $1.65 Million Stock Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)

March 9, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Price Targets on NVIDIA Rise in Front of Earnings
By Sarah Horvath | February 24, 2025
View Price Targets on NVIDIA Rise in Front of Earnings
Archer Aviation Stock Skids: Mistaking Progress for Bad News?
By Chris Markoch | February 24, 2025
View Archer Aviation Stock Skids: Mistaking Progress for Bad News?
Joby Aviation: From Prototype to Profitability
By Jeffrey Neal Johnson | March 11, 2025
View Joby Aviation: From Prototype to Profitability
Tesla Stock: Finding a Bottom May Take Time
By Chris Markoch | March 4, 2025
View Tesla Stock: Finding a Bottom May Take Time
Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
By Thomas Hughes | March 18, 2025
View Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?

EXAS, HOLX, FOLD, TAK, and SNY Company Descriptions

Exact Sciences NASDAQ:EXAS

$45.67 -1.42 (-3.02%)

Closing price 04:00 PM Eastern

Extended Trading

$45.76 +0.09 (+0.19%)

As of 05:29 PM Eastern

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Amicus Therapeutics NASDAQ:FOLD

$8.62 -0.07 (-0.81%)

As of 04:00 PM Eastern

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Hologic NASDAQ:HOLX

$60.80 -1.09 (-1.76%)

Closing price 04:00 PM Eastern

Extended Trading

$61.44 +0.64 (+1.06%)

As of 05:31 PM Eastern

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. The company also offers breast cancer care solutions in the areas of radiology, breast surgery, pathology, and treatment, such as 3D digital mammography systems, image analytics software, reading workstations, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, specimen radiology, and connectivity solutions; and breast conserving surgery products. In addition, it provides MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids and polyps in the uterus; NovaSure Endometrial Ablation System to treat abnormal uterine bleeding; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; Acessa ProVu system to treat various fibroids; and CoolSeal portfolio, such as bipolar vessel sealing devices. Further, the company offers Horizon DXA, a dual energy X-ray system; and Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. It sells its products through direct sales, service forces, independent distributors, and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.

Sanofi NASDAQ:SNY

$55.45 -0.48 (-0.86%)

Closing price 04:00 PM Eastern

Extended Trading

$55.46 +0.00 (+0.01%)

As of 05:23 PM Eastern

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Takeda Pharmaceutical NYSE:TAK

$15.05 +0.04 (+0.27%)

Closing price 03:58 PM Eastern

Extended Trading

$15.08 +0.04 (+0.23%)

As of 05:39 PM Eastern

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time